DERMAPHARM HLDG INH O.N. overview

EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Annual Report Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance 28.03.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance Consolidated revenue up 4.0% to EUR 1,180.8 million (Unadjusted) consolidated EBITDA increases by 10.2% to EUR 308.9 million, unadjusted EBITDA...

EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Preliminary Results Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA 14.03.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA Consolidated revenue up 4.0% to EUR 1,180.8 million, driven by strong organic growth in the "Branded...

EQS-News: Dermapharm Holding SE / Key word(s): Quarterly / Interim Statement/9 Month figures Dermapharm Holding SE posts strong results for Q3 2024, Arkopharma (France) back above prior-year EBITDA levels for first time 14.11.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE posts strong results for Q3 2024, Arkopharma (France) back above prior-year EBITDA levels for first time Consolidated revenue up 2.7% to EUR 890.1 million....

EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Half Year Report Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies 27.08.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies Impressive organic...

EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Preliminary Results Sustained organic growth in high-margin existing branded pharmaceutical business 14.08.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE: Sustained organic growth in high- margin existing branded pharmaceutical business Strong organic growth of existing branded pharmaceutical business across virtually every market compensates for effects from...

EQS-News: Dermapharm Holding SE / Key word(s): AGM/EGM Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share 27.06.2024 / 18:15 CET/CEST The issuer is solely responsible for the content of this announcement. Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share 2024 outlook confirmed Board of Management and Supervisory Board actions ratified with large majority Shareholders resolve dividend payment of EUR...